Endonovo Therapeutics Inc.’s (ENDV) Electroceutical Device Brings Rapid Pain Relief, Leads to 30-40% Decrease in Post-Surgical Narcotic Prescriptions
Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025 Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions…